• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Biomarin Pharmaceutical

Biomarin Pharmaceutical

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Global Pompe Disease Therapeutics Development Pipeline Review 2015 - Research and Markets

    Global Pompe Disease Therapeutics Development Pipeline Review 2015 - Research and Markets

  2. Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review 2015 - Research and Markets

    Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review 2015 - Research and Markets

  3. Biopharmaceutical Market - Forecast (2015 - 2020) - Market Dominated by North America - Research and Markets

    Biopharmaceutical Market - Forecast (2015 - 2020) - Market Dominated by North America - Research and Markets

  4. Sarepta Shares Plunge as FDA Raises Doubts About Drug

    Sarepta Shares Plunge as FDA Raises Doubts About Drug

  5. Investing in Hidden Assets

    Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.

  6. A Young Power Couple's Kickstart Portfolio

    With "massive" student debt loads receding in the rearview mirror, a young professional couple fires up their investment plan.

  7. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  8. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

  9. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

  10. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.